📰 What This Document Is 📣

This filing is an 8-K, which is a required SEC form used to announce major corporate events that shareholders and the public should know about immediately. In simple terms, it’s the company’s way of saying, "Hey, pay attention! We have big news." The announcement, made on April 20, 2026, is focused on two major leadership appointments designed to support the commercial launch of Neurogene's gene therapy candidate.

👉 The core takeaway is that Neurogene is maturing from a research-stage biotech into a company focused on market readiness, evidenced by these high-level hires.

🧬 What Neurogene Does 🏥

Neurogene Inc. is a clinical-stage biotechnology company dedicated to creating genetic medicines for patients and families battling rare neurological diseases. Instead of just treating symptoms, Neurogene aims to use a "biology-first approach" paired with advanced delivery systems to develop purpose-built genetic treatments.

👉 The company's current mission is centered on advancing its lead therapy, NGN-401, which is designed as a potential best-in-class, one-time treatment for Rett syndrome.

🔬 How Neurogene’s Technology Works 🧬

Neurogene’s scientific edge lies in its ability to deliver genetic medicine to the body safely and effectively. They achieve this using a proprietary technology known as EXACT™ transgene regulation. This technology is critical because it ensures that the genetic medicine does what it needs to do without causing unwanted side effects.

👉 The proprietary EXACT™ technology is key to the company's scientific foundation, enabling them to develop gene therapies that are targeted and reliable.

🌟 Christina Shafer: Commercial Strategy 👩‍💼

This section details the arrival of Christy Shafer, a major hire responsible for guiding Neurogene's commercial efforts. Her expertise is particularly valuable because she has spent her career building commercial launch teams for rare neurological diseases.

• New Role: Christy Shafer has been appointed as the Chief Commercial Officer (CCO).
• Why it Matters: This appointment signals that the company is moving intensely toward commercialization. Her deep experience in this specific field—rare neurological diseases—is directly linked to the success of NGN-401.
• Shafer’s Track Record: She has over 20 years of experience building and leading commercial organizations. Her past roles include serving at Avidity Biosciences (a company acquired by Novartis) and at Marinus Pharmaceuticals, where she led the launch of Ztalmy® for seizures associated with CDKL5 deficiency disorder.

🧩 Christine Mikail: Board Leadership ♟️

The filing also announces the addition of Christine Mikail, J.D., to the Board of Directors. Board appointments are crucial because the board provides high-level strategic oversight and governance to ensure the company is making sound long-term decisions.

• New Role: Christine Mikail, who previously served as President and CFO at Neurogene, has joined the Board of Directors.
• Expertise: Ms. Mikail brings deep knowledge in several areas, including strategic transactions, capital formation, and corporate development.
• Impact: Her inclusion strengthens the Board by adding specialized financial and operational judgment, helping the company structure its long-term goals as it prepares for growth.

💬 Management Commentary and Confidence 🙏

The leaders of Neurogene provided several quotes that paint a clear picture of the company’s confidence and focus. These quotes help interpret how serious the company is about its upcoming product launches and general growth.

• CEO’s Perspective: Rachel McMinn, Founder and CEO, emphasized that Shafer is a "proven commercial leader" who will "guide our commercial strategy and launch readiness for NGN-401."
• Mikail’s Commitment: Ms. Mikail stated she "look[s] forward to contributing my experience and perspective to Neurogene’s long-term strategy as a member of the Board."
• Shafer’s Vision: Ms. Shafer expressed enthusiasm, noting that the company's "differentiated approach to gene therapy represents a meaningful opportunity to transform outcomes for patients with devastating neurological diseases."

🚀 The Focus on NGN-401 and Rett Syndrome 💡

The central focus of all these appointments is the gene therapy product, NGN-401. This section explains what the drug is, what condition it treats, and why getting this drug to market is the company's most important goal.

• The Product: NGN-401 is the lead gene therapy program for Neurogene.
• The Target: It is positioned as a potential best-in-class, one-time treatment for Rett syndrome.
• Why it Matters: Because the treatments for these rare conditions are often devastating, the successful commercialization of NGN-401 represents a massive, life-changing opportunity for the company and its patients.

🧑‍🔬 Building the Commercial Machine 🏗️

The hiring of the Chief Commercial Officer (CCO) is not just a name change; it's the act of building an entire business structure designed to sell and support a complex therapy.

• Core Goal: Shafer’s team will be tasked with developing the entire commercial strategy needed for NGN-401.
• The Significance: Building a commercial organization for a novel gene therapy requires deep expertise in regulatory navigation, sales channel development, and handling highly specialized medical sales, all of which Shafer brings to the table.

📚 Company Background and Expertise 📚

Neurogene is more than just a drug developer; it is a company built on a specific scientific approach. This section summarizes its general scope, making it clear that the mission is focused intensely on rare neurological disorders.

• Mission: To develop "life-changing genetic medicines" for people and families impacted by devastating neurological diseases.
• Technology Focus: Their strategy revolves around a "biology-first approach paired with optimized delivery," ensuring their therapeutic solutions are highly customized and effective.

📞 Important Contact Information 📧

For those interested in following Neurogene's progress, the filing provided dedicated contacts for corporate communications and investor relations. These contacts are essential for journalists, investors, and partners.

• Corporate Communications: Mike Devine, Executive Director, with the email [email protected].
• Investor Relations: Lina Li, Executive Director, with the email [email protected].

🧠 The Analogy 💡

Think of Neurogene like a highly advanced, specialized rocket (NGN-401) that is ready to launch into a critical orbit (the patient market). Before it can launch, the company needs two things: a specialized, seasoned mission control team (Christy Shafer, the CCO) to manage the launch sequence, and expert consultants (Christine Mikail) to ensure the entire operation's financial and operational foundation is rock solid. The 8-K is simply the moment the rocket team officially gets its mission control center staffed up.

🧩 Final Takeaway 💡

Neurogene is making critical moves to professionalize its structure, signaling a confident transition from a purely clinical research entity to a full-fledged commercial pharmaceutical player. The immediate focus is leveraging Shafer's specialized commercial expertise to prepare for the market launch of NGN-401 for Rett syndrome.